pipeline

Our research and development is focused on applying excellent science to discover and develop potential new synthetic DNA vaccines with the goal of creating first-in-class or best-in-class therapeutics and/or preventives.

Collaborator Vaccines & Studies
Internally Funded
Partner Funded

Disease	Vaccine Program	Antigen	Partner/ Funding/ Sponsor
Inovio Studies
Cervical dysplasia HPV Type 16/18 Info	VGX-3100	E6, E7		Therapeutic Info: Milestone: Enrolling international phase II study; aiming for results in the first quarter of 2014 Highlight: Phase I trial shows vaccine produces "killer T-cells" that kill cervical dysplasia cells
Prostate cancer	INO-5150	PSA, PSMA		Therapeutic Info: Milestone: Aiming for phase I study launch in 2013 Highlight: Successful large animal results reinforce potential utility of Inovio's DNA vaccine approach for treating cancers
Hepatitis C Genotype 1a & 1b	INO-8000	NS3/4A, NS4B, NS5A	VGX International, Inc.	Therapeutic Info: Milestone: Initiate phase I/IIa in HCV infected individuals in the fourth quarter of 2013 Highlight: Rhesus macaques mounted strong HCV-specific T cell immune responses strikingly similar to those reported in patients who have cleared the virus on their own.
HIV Clade B	PENNVAX^®-B	gag, pol, env	HIV Vaccine Trials Network	Preventive & Therapeutic Info: Milestone: Publication of data expected in July Highlight: Significant vaccine-specific T-cell responses observed in 89% of phase I subjects
HIV Clades A, C, D	PENNVAX^®-G	env, gag	USMHRP/NIAID	Preventive & Therapeutic Info: Milestone: Complete enrollment at three study centers except the U.S. Highlight: PENNVAX®-G plus MVA boost achieves 100% antigen-specific T-cell immune responses and safety with interim data
HIV Clades A, C	PENNVAX^®-GP	gag, pol, env	NIH/NIAID	Preventive & Therapeutic Info: Milestone: Initiate phase I study in 2013 Highlight: PENNVAX-GP generated robust antigen-specific T-cell responses and protection from the virus in pre-clinical studies
Influenza - UniversalPandemic	VGX-3400X	HA, NA, NP		Preventive Info: Milestone: Phase I completed Highlight: Demonstrated immune responses against six unmatched H5N1 strains
Influenza - UniversalSeasonal (18-55 years)	H1 + H5	HA	NIH Director's Office Transformative Research Award	Preventive Info: Milestone: Phase I data reported Highlight: Vaccine showed protective immune responses in humans against the nine key H1N1 flu strains of past 100 years, including 1918 pandemic flu
Influenza - Universal Seasonal (65+ years)	Various	HA	NIH Director's Office Transformative Research Award	Preventive Info: Milestone: Phase I data reported Highlight: Vaccine showed protective immune responses in 40% of elderly trial subjects compared with a 20% response rate in the elderly subjects who received the seasonal flu vaccine alone
Malaria	Various	Various	MVI/PATH	Preventive Info: Milestone: Initiate phase I/IIa study in 2014
Collaborator Vaccines & Studies
Leukemia CML & AML	WT1 Vaccine	WT1	Owned/funded by U. of Southampton/ LLR and CRUK* (Inovio electroporation)	Therapeutic Info: Milestone: Additional phase II results 2013 Highlight: Preclinical data showed strong induction of antigen-specific CD8+ T cells; killed human tumor cells expressing WT1.
Hepatitis C	ChronVac-C^®	NS3/4A	Owned by ChronTech (Inovio electroporation)	Therapeutic Info: Milestone: Phase II data reported Highlight: Phase I results demonstrated a complete and rapid viral response in 83% of participants

* Leukaemia and Lymphoma Research and Cancer Research UK

Page 'Breadcrumb' Navigation